Grant: CIHR Fellowship
Université Laval
$135,000.00
Rethinking Huntington's disease: using healthy plasma proteins to ameliorate pathology
FY 2023-24
Summary
Huntington's disease (HD) is a neurodegenerative disorder caused by a single defective gene known as huntingtin (HTT). This disease is characterized by uncontrolled movements, a decline of thinking ability as well as psychiatric problems. The life span of affected individuals is usually 10 to 30 years after the appearance of symptoms. In this disease, an abnormal form of a protein referred to as mutant Huntingtin (mHtt) accumulates in brain cells disrupting their normal function and eventually leading to their death. Recently, the Cicchetti group utilized a model system called "parabiosis" in which mice are surgically sutured to create the joint circulatory system and has provided exciting new evidence showing reduced pathology in the diseased (HD) mice that were paired to normal animal. This study demonstrated the involvement of circulating factors from healthy blood in diluting/ameliorating disease pathology. Building on this new data, we designed a project which aims to identify the beneficial elements contained in healthy blood and to understand how they ameliorate brain health. To achieve this goal, we will isolate human plasma proteins capable of migrating from the blood into the brain because they will likely be the most neuroprotective factors. We will then evaluate if these proteins improve the survival and function of neurons and non-neuronal cells in a dish but also in a mouse model of HD. This project will help us identify circulating factors in healthy plasma that may prevent the death of brain cells and that therefore could be useful in treating various disease features. Additionally, outcome of this study may encourage transfusion of healthy human plasma as a potential therapeutic strategy to treat HD.
Department
Program
CIHR Fellowship
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
493261
Name
Cardim Pires Thyago R
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Health Research Training A - Post-PhD (HTA)
Projecttitle
Rethinking Huntington's disease: using healthy plasma proteins to ameliorate pathology
Programtype2
Fellowship Programs
Orgnameinp2
Université Laval
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Blood Brain Barrier; Huntington'S Disease; Mutant Huntingtin Protein; Neurodegenerative Diseases; Neuroprotection; Parabiosis; Plasma; Proteomics
Abstract
Huntington's disease (HD) is a neurodegenerative disorder caused by a single defective gene known as huntingtin (HTT). This disease is characterized by uncontrolled movements, a decline of thinking ability as well as psychiatric problems. The life span of affected individuals is usually 10 to 30 years after the appearance of symptoms. In this disease, an abnormal form of a protein referred to as mutant Huntingtin (mHtt) accumulates in brain cells disrupting their normal function and eventually leading to their death. Recently, the Cicchetti group utilized a model system called "parabiosis" in which mice are surgically sutured to create the joint circulatory system and has provided exciting new evidence showing reduced pathology in the diseased (HD) mice that were paired to normal animal. This study demonstrated the involvement of circulating factors from healthy blood in diluting/ameliorating disease pathology. Building on this new data, we designed a project which aims to identify the beneficial elements contained in healthy blood and to understand how they ameliorate brain health. To achieve this goal, we will isolate human plasma proteins capable of migrating from the blood into the brain because they will likely be the most neuroprotective factors. We will then evaluate if these proteins improve the survival and function of neurons and non-neuronal cells in a dish but also in a mouse model of HD. This project will help us identify circulating factors in healthy plasma that may prevent the death of brain cells and that therefore could be useful in treating various disease features. Additionally, outcome of this study may encourage transfusion of healthy human plasma as a potential therapeutic strategy to treat HD.
Competitiondate
202310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Cardim Pires, Thyago R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~